2007
High Resolution Array-CGH in Splenic Marginal Zone B-Cell Lymphoma: Correlation of Copy Number Imbalances with HCV Status and Prognostic Categories.
Novara F, Arcaini L, Merli M, Passamonti F, Zibellini S, Montanari F, Rizzi S, Rumi E, Pascutto C, Paulli M, Zuffardi O, Lazzarino M. High Resolution Array-CGH in Splenic Marginal Zone B-Cell Lymphoma: Correlation of Copy Number Imbalances with HCV Status and Prognostic Categories. Blood 2007, 110: 2620. DOI: 10.1182/blood.v110.11.2620.2620.Peer-Reviewed Original ResearchSplenic marginal zone B-cell lymphomaMarginal zone B-cell lymphomaPrognostic categoriesNumber of CNAsB-cell lymphomaCopy number alterationsHCV casesVillous lymphocytesGenetic alterationsAdverse prognostic factorRecent multicentre studyPeripheral blood lymphocytesDifferent prognostic categoriesFrequent copy number alterationsGroups of ptsImmunoglobulin variable heavy chain genesSpecific genetic abnormalitiesSpecific genetic alterationsVariable heavy chain genesAutoimmune backgroundHCV infectionHCV statusPrognostic factorsClinical featuresMulticentre study
2006
Primary nodal marginal zone B‐cell lymphoma: clinical features and prognostic assessment of a rare disease
Arcaini L, Paulli M, Burcheri S, Rossi A, Spina M, Passamonti F, Lucioni M, Motta T, Canzonieri V, Montanari M, Bonoldi E, Gallamini A, Uziel L, Crugnola M, Ramponi A, Montanari F, Pascutto C, Morra E, Lazzarino M, Linfomi I. Primary nodal marginal zone B‐cell lymphoma: clinical features and prognostic assessment of a rare disease. British Journal Of Haematology 2006, 136: 301-304. PMID: 17233821, DOI: 10.1111/j.1365-2141.2006.06437.x.Peer-Reviewed Original ResearchConceptsFollicular Lymphoma International Prognostic IndexOverall survivalClinical featuresPrimary nodal marginal zone B-cell lymphomaHepatitis C virus serologyMarginal zone B-cell lymphomaNodal marginal zone B-cell lymphomaC virus serologyStage IV diseaseWorse overall survivalInternational Prognostic IndexB-cell lymphomaWorse OSPrognostic indexVirus serologyPrognostic assessmentRare diseaseMultivariate analysisLactate dehydrogenaseDiseasePatientsPrognosisLymphomaSerologyClinical Features and Prognostic Assessment of Nodal Marginal Zone B-Cell Lymphoma, a Rare Disease with Follicular-Like Behaviour.
Arcaini L, Paulli M, Burcheri S, Boveri E, Rossi A, Spina M, Passamonti F, Montanari M, Gallamini A, Uziel L, Crugnola M, Montanari F, Pascutto C, Morra E, Lazzarino M. Clinical Features and Prognostic Assessment of Nodal Marginal Zone B-Cell Lymphoma, a Rare Disease with Follicular-Like Behaviour. Blood 2006, 108: 2427. DOI: 10.1182/blood.v108.11.2427.2427.Peer-Reviewed Original ResearchMarginal zone B-cell lymphomaPrimary nodal marginal zone B-cell lymphomaNodal marginal zone B-cell lymphomaEvent-free survivalB-cell lymphomaShorter event-free survivalPrimary nodal marginal zone lymphomaFLIPI scoreMarginal zone lymphomaNodal marginal zone lymphomaClinical featuresB symptomsHCV serologyOverall survivalBorderline significancePrognostic assessmentLower riskRare diseaseMedian age 63 yearsPeripheral blood involvementAge 63 yearsPositive HCV serologyWorse overall survivalOverall response rateLymph node localizationNongastric Marginal-Zone B-Cell MALT Lymphoma: Prognostic Value of Disease Dissemination
Arcaini L, Burcheri S, Rossi A, Passamonti F, Paulli M, Boveri E, Brusamolino E, Orlandi E, Molteni A, Pulsoni A, Cox MC, Orsucci L, Fabbri A, Frezzato M, Voso MT, Zaja F, Montanari F, Pascutto C, Morra E, Cortelazzo S, Lazzarino M. Nongastric Marginal-Zone B-Cell MALT Lymphoma: Prognostic Value of Disease Dissemination. The Oncologist 2006, 11: 285-291. PMID: 16549813, DOI: 10.1634/theoncologist.11-3-285.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAnthracyclinesAntibodies, MonoclonalAntigens, CD20Antineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsBone Marrow NeoplasmsChemotherapy, AdjuvantFemaleFollow-Up StudiesHumansItalyLymphatic MetastasisLymphoma, B-Cell, Marginal ZoneMaleMiddle AgedMultivariate AnalysisPrognosisRadiotherapy, AdjuvantRetrospective StudiesConceptsBone marrow involvementMarrow involvementNodal involvementClinical featuresSurvival timeBone marrowMedian event-free survival timeB-cell MALT lymphomaMedian overall survival timeDisease disseminationEvent-free survival timeB-cell mucosaStage IV diseaseOverall survival timeLymphoid tissue lymphomaMarginal zone lymphomaLonger EFSNodal diseaseShorter OSOS timeTissue lymphomaWaldeyer's ringPoor outcomePrognostic significancePrognostic valueRole of the molecular staging and response in the management of follicular lymphoma patients
Arcaini L, Colombo N, Bernasconi P, Calatroni S, Passamonti F, Orlandi E, Bonfichi M, Burcheri S, Della Porta M, Rumi E, Montanari F, Algarotti A, Pascutto C, Lazzarino M. Role of the molecular staging and response in the management of follicular lymphoma patients. Leukemia & Lymphoma 2006, 47: 1018-1022. PMID: 16840191, DOI: 10.1080/10428190500467834.Peer-Reviewed Original ResearchConceptsBcl-2/IgH rearrangementBcl-2 rearrangementBcl-2-negative patientsBcl-2 positive patientsPeripheral bloodMedian EFSMolecular respondersBone marrowNegative patientsPositive patientsClinical featuresBetter EFSIgH rearrangementsMedian event-free survivalBcl-2 negative casesEvent-free survivalFirst-line therapyCohort of patientsFollicular lymphoma patientsBcl-2Onset of diseaseMolecular responseBcl-2-positive casesInitial stagingLymphoma patients